The development of a class of immunotherapeutics, the calcium pterins,
beginning with Ca Pterin·2Cl (Ca-Pterin) and culminating with calcium pterin6-carboxylate chelate (CP6CC) for several immunologically-related preclinicaland clinical indications is reviewed here.
 |
| Immunotherapy |
A preliminary analysis of their immuno-mechanisms of action is
discussed. The preclinical murine models first tested with CaPterin and
dipterinyl calcium pentahydrate (DCP), a dimerized version of CaPterin, were
four murine breast tumor models. These four models included: C3H/HeN-MTV+
female mice with spontaneous mammary gland adenocarcinomas; Mammary EMT6
allografts implanted in nonimmune female Balb/c mice; MDA-MB-231 human breast
tumor xenographs in SCID mice; and MDA-MB-231 human breast tumor xenographs in
athymic nude mice. An analysis of the differing tumor responses in these breast
tumor models led to the determination that B-cell antibody-based antitumor
mechanisms were involved. A transgenic hepatitis B murine model and a
diabetes-induced obese (DIO) type 2 diabetes murine model were also tested with
DCP, giving positive results. Read more>>>>>>>
No comments:
Post a Comment